Advanced Enzyme Technologies Q4 Review - Uncertainty Around Near-Term Growth: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Advanced Enzyme Technologies Ltd.’s Q4 FY21 operating performance came in below our estimates mainly on account of pressure on margins.
Raw material inflation, higher logistics costs and addition of new subsidiary from January 2021 resulted in margin contraction.
Management has not given any guidance for FY22 on account of uncertainty prevailing due to Covid-19.
While the biocatalyst and nutraceuticals segments are expected to report strong growth, animal nutrition and bio-processing (food as well as non-food) are under pressure.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.